Relevant bibliographies by topics / Type 1 diabetes mellitu

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Type 1 diabetes mellitu'

Author: Grafiati
Published: 9 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Type 1 diabetes mellitu.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Type 1 diabetes mellitu"

1

Duarte, Nietsnie, Izabel Hazin, Carolina Vilar, Amanda Guerra, Luana Metta, Danielle Garcia, and Rosália Freire. "INTELLIGENCE AND DIABETES MELLITUS TYPE 1." Psicologia, Saúde & Doença 18, no. 2 (July 25, 2017): 462–73. http://dx.doi.org/10.15309/17psd180214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cinek, Ondřej, and Zdeněk Šumník. "Type 1 diabetes: etiology and epidemiology." Vnitřní lékařství 65, no. 4 (April 1, 2019): 235–47. http://dx.doi.org/10.36290/vnl.2019.041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kaufman, F. R. "Type 1 Diabetes Mellitus." Pediatrics in Review 24, no. 9 (September 1, 2003): 291–300. http://dx.doi.org/10.1542/pir.24-9-291.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gregory, J. M., D. J. Moore, and J. H. Simmons. "Type 1 Diabetes Mellitus." Pediatrics in Review 34, no. 5 (May 1, 2013): 203–15. http://dx.doi.org/10.1542/pir.34-5-203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gregory, Justin M., Daniel J. Moore, and Jill H. Simmons. "Type 1 Diabetes Mellitus." Pediatrics In Review 34, no. 5 (May 1, 2013): 203–15. http://dx.doi.org/10.1542/pir.34.5.203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kaufman, Francine Ratner. "Type 1 Diabetes Mellitus." Pediatrics In Review 24, no. 9 (September 1, 2003): 291–300. http://dx.doi.org/10.1542/pir.24.9.291.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Syed, Fatima Z. "Type 1 Diabetes Mellitus." Annals of Internal Medicine 175, no. 3 (March 2022): ITC33—ITC48. http://dx.doi.org/10.7326/aitc202203150.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lee, Myung-Shik, and Kyoung-Ah Kim. "Type 1 Diabetes Mellitus." Journal of the Korean Medical Association 52, no. 7 (2009): 677. http://dx.doi.org/10.5124/jkma.2009.52.7.677.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Suzuki, Takahiro, Kenji Takahashi, Satoshi Miyamoto, Hiroyuki Ueno, Sato Takekawa, Atsushi Yoshida, and Motohiro Fujita. ""Type 1 on Type 2" Diabetes Mellitus: Autoimmune Type 1 Diabetes Superimposed on Established Type 2 Diabetes." Internal Medicine 46, no. 24 (2007): 1957–62. http://dx.doi.org/10.2169/internalmedicine.46.0282.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Unni, Shiju Raman, Hani Naguib, and Mary Mccallum. "Knowledge, Beliefs and Practices of People diagnosed with Type-1 Diabetes towards Diabetes Mellitus and Diabetic Foot Syndrome." Diabetes and Islet Biology 5, no. 1 (January 11, 2022): 01–08. http://dx.doi.org/10.31579/2641-8975/025.

Full text
Abstract:
Background: Diabetes Mellitus (DM) is associated with significant morbidity and mortality. Diabetic foot syndrome is one of the most common devastating preventable complications of diabetes mellitus (DM). Objectives: We aimed to evaluate the knowledge, Beliefs and Practices (KBP) among Omani patients with type 1 diabetes mellitus (T1DM) regarding DM and Diabetes foot. Design: A cross sectional descriptive study was used. Settings: A secondary care, polyclinic named Bawshar in Muscat, Oman where patients were seen three days per week. Sample Size:A convenient sample of 100 participants between age group 16 to 30 years were involved. Materials and methods: A validated semi- structured questionnaire was used to assess KBP of T1DM with six domains. During the study period from November 2019 to December 2019. .The data was analysed by using Statistical Package for the Social Sciences (SPSS) Statistics Inc., Chicago, US version 20. Results: There were 50 females, 50 males; 5 % of patients were illiterate and 30% of them were working. 65% were students. Only 50% checked their foot regularly and only 55% check there blood glucose regularly .57% don’t know the cause of diabetes, 25% don’t know the complications of the same while 20% don’t know cause of diabetic foot and 25% don’t know the symptoms of diabetic foot. 20% beliefs checking blood glucose is the responsibility of the doctor and 85% beliefs walking bare foot is high risk factor for DM foot. Conclusions: In reality healthcare providers must be trained to counsel people with DM to plan adequate interventions that enable an understanding of the offered information. A well-structured ,Behaviour change counselling (BCC) like Motivational interviewing (MI)are considered the ideal practices for this patients, to prevent DM complications.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Type 1 diabetes mellitu"

1

Jamali, Reza. "Peripheral Hypoglycaemic Neuropathy in Type 1 Diabetic Rats : Morphologic and Metabolic Studies." Doctoral thesis, Linköping : Univ, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-7978.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dekki, Wenna Nancy. "Serum proteins in type 1 diabetes /." Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-057-2/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Elfvin, Åkesson Karin. "Genetic analysis of type 1 diabetes /." Stockholm : Karolinska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-321-4/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hoogma, Roeland Petrus Leonardus Maria. "Subcutaneous insulin infusion in type 1 diabetes mellitus." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2006. http://dare.uva.nl/document/29301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wong, Xing-Wei. "Model-Based Therapeutics for Type 1 Diabetes Mellitus." Thesis, University of Canterbury. Mechanical Engineering, 2008. http://hdl.handle.net/10092/1573.

Full text
Abstract:
The incidence of Type 1 diabetes is growing yearly. Worryingly, the aetiology of the disease is inconclusive. What is known is that the total number of affected individuals, as well as the severity and number of associated complications are growing for this chronic disease. With increasing complications due to severity, length of exposure, and poor control, the disease is beginning to consume an increasingly major portion of healthcare costs to the extent that it poses major economic risks in several nations. Research has shown that intensive insulin therapy aimed at certain minimum glycosylated haemoglobin threshold levels reduces the incidence of complications by up to 76% compared to conventional insulin therapy. Moreover, the effects of such intensive therapy regimes over a 6.5y duration persists for at least 10y after, a so called metabolic memory. Thus, early intervention can slow the momentum of complications far more easily than later intervention. Early, safe, intensive therapy protocols offer potential solutions to the growing social and economic effects of diabetes. Since the 1970s, the artificial endocrine pancreas has been heralded as just this type of solution. However, no commercial product currently exists, and ongoing limitations in sensors and pumps have resulted in, at best, modest clinical advantages over conventional methods of insulin administration or multiple daily injection. With high upfront costs, high costs of consumables, significant complexity, and the extensive infrastructure and support required, these systems and devices are only used by 2-15% of individuals with Type 1 diabetes. Clearly, there is an urgent need to address the large majority of the Type 1 diabetes population using conventional glucose measurement and insulin administration. For these individuals, current conventional or intensive therapies are failing to deliver recommended levels of glycaemic control. This research develops an understanding of clinical glycaemic control using conventional insulin administration and glucose measurement techniques in Type 1 diabetes based on a clinically validated in silico virtual patient simulation. Based on this understanding, a control protocol for Type 1 diabetes that is relatively simple and clinically practical is developed. The protocol design incorporates physiological modelling and engineering techniques to adapt to individual patient clinical requirements. By doing so, it produces accurate, patient-specific recommendations for insulin interventions. Initially, a simple, physiological compartmental model for the pharmacokinetics of subcutaneously injected insulin is developed. While the absorption process itself is subject to significant potential variability, such models enable a real-time estimation of plasma insulin concentration. This information would otherwise be lacking in the clinical environment of outpatient Type 1 diabetes treatment due to the inconvenience, cost, and laboratory turnaround for plasma insulin measurements. Hence, this validated model offers significant opportunity to optimise therapy selection. An in silico virtual patient simulation tool is also developed. A virtual patient cohort is developed on patient data from a representative cohort of the broad diabetes population. The simulation tool is used to develop a robust, adaptive protocol for prandial insulin dosing against a conventional intensive insulin therapy, as well as a controls group representative of the general diabetes population. The effect on glycaemic control of suboptimal and optimal, prandial and basal insulin therapies is also investigated, with results matching clinical expectations. To gauge the robustness of the developed adaptive protocol, a Monte Carlo analysis is performed, incorporating realistic and physiological errors and variability. Due to the relatively infrequent glucose measurement in outpatient Type 1 diabetes, a method for identifying the diurnal cycle in effective insulin sensitivity and modelling it in retrospective patient data is also presented. The method consists of identifying deterministic and stochastic components in the patient effective insulin sensitivity profile. Circadian rhythmicity and sleep-wake phases have profound effects on effective insulin sensitivity. Identification and prediction of this rhythm is of utmost clinical relevance, with the potential for safer and more effective glycaemic control, with less frequent measurement. It is thus a means of further enhancing any robust protocol and making it more clinically practical to implement. Finally, this research presents an entire framework for the realistic, and rapid development and testing of clinical glycaemic control protocols for outpatient Type 1 diabetes. The models and methods developed within this framework allow rapid and physiological identification of time-variant, patient-specific, effective insulin sensitivity profiles. These profiles form the responses of the virtual patient and can be used to develop and robustly test clinical glycaemic control protocols in a broad range of patients. These effective insulin sensitivity profiles are also rich in dynamics, specifically those circadian in nature which can be identified, and used to provide more accurate glycaemic prediction with the potential for safer and more effective control.
APA, Harvard, Vancouver, ISO, and other styles
6

Carvalho, Tiago Filipe Cruz. "Type 1 diabetes mellitus effects on mitochondrial function." Master's thesis, Universidade de Aveiro, 2011. http://hdl.handle.net/10773/7520.

Full text
Abstract:
Mestrado em Bioquímica-Métodos Biomuleculares
Despite type 1 diabetes mellitus being more rare, it has an autoimmune origin and appears early in life, greatly affecting its quality. With the aim of better understand the molecular mechanisms underlying the observed phenotypic alterations in the skeletal muscle from diabetic patients, it was planned an experimental protocol using 20 Wistar rats 8 weeks old, randomly divided in two groups (n=10). The animals from one group were injected with 60mg/Kg of streptozotocin (STZ), while the others were injected with vehicle buffer. Four months after STZ injection, rats were confirmed as diabetic, considering hyperglycemia and body weight loss. After animals sacrifice, gastrocnemius muscles were excised and used for mitochondria subpopulations (subsarcolemmal (SS) and intermyofibrillar (IMF)) isolation. mtDNA-to-muscle mass ratio suggest an increased biogenesis of SS mitochondria in the STZ animals, paralleled by a decreased protein content per mitochondrion, in opposite to the observed in IMF mitochondria. The BN-PAGE profile revealed a slight difference of the oxidative phosphorylation complexes organization between mitochondrial subpopulations, apparently not affected by STZ administration. Mitochondrial proteolysis analysis, evaluated through zymography, revealed two proteases with molecular weights around 15 and 25 KDa, with the smaller one presenting STZinduced significant decreased activity in IMF mitochondria. A similar behavior was observed for paraplegin, a subunit of m- AAA proteolytic system, and mitofilin, a protein involved in cristae organization. Interestingly, these protein levels were higher in SS mitochondria from diabetic animals. With this work it was verified that subsarcolemmal mitochondria are not so affected by STZ administration as IMF mitochondria. The decreased activity of the protein quality control system seems to be associated with the morphological and biochemical alterations observed in the mitochondria interspersed in fibrils.
Apesar de a diabetes tipo 1 ser uma das formas mais raras de diabetes mellitus, tem uma origem auto-imune e aparece precocemente na vida de um indivíduo afectando grandemente a qualidade da mesma. No sentido de melhor compreender os mecanismos moleculares subjacentes às alterações fenotípicas observadas no músculo esquelético dos pacientes diabéticos, delineou-se um protocolo experimental com 20 ratos Wistar com 8 semanas de idade, aleatoriamente divididos em dois grupos (n=10). Os animais de um dos grupos foram injectados com 60mg/Kg de streptozotocina (STZ), e os outros com veículo. Após 4 meses, os ratos injectados com STZ foram confirmados como diabéticos, tendo em consideração a hiperglicemia e a perda de massa corporal. Após o sacrifício dos animais foram retirados os músculos gastrocnemius, a partir dos quais foram isoladas as duas subpopulações mitocondriais (subsarcolemal (SS) e intermiofibrilar (IMF)). A análise da razão mtADN-massa muscular sugere que a administração de STZ induziu o aumento da biogénese mitocondrial SS associado a um decréscimo do teor proteico mitocondrial, ao contrário do observado nas mitocôndrias IMF. O perfil de BNPAGE revelou uma ligeira diferença entre a organização dos complexos da fosforilação oxidativa entre ambas as subpopulações mitocondriais, aparentemente não afectada pela administração de STZ. A análise da proteólise mitocondrial, efectuada por zimografia, evidenciou duas proteases com 15 e 25 KDa, tendo-se observado uma diminuição acentuada da actividade da protease com menor peso molecular nas mitocôndrias IMF dos animais diabéticos. Uma tendência semelhante foi observada para a expressão da subunidade paraplegina do sistema proteolítico m-AAA e para a mitofilina, uma proteína envolvida na organização da membrana interna mitocondrial. Curiosamente, nas mitocôndrias SS dos animais diabéticos verificaram-se níveis mais elevados destas proteínas. Com este estudo verificou-se que no gastrocnemius, as mitocôndrias IMF são mais afectadas pela diabetes mellitus tipo 1 do que as SS. A diminuição da actividade do sistema de controlo da qualidade proteica parece estar associada às alterações morfológicas e bioquímicas observadas nas mitocôndrias localizadas entre as fibrilas.
APA, Harvard, Vancouver, ISO, and other styles
7

Elrayah-Eliadarous, Hind. "Economic burden of diabetes on patients and their families in Sudan /." Stockholm, 2007. http://diss.kib.ki.se/2007/978-91-7357-450-1/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Walldén, Jenny. "Studies of immunological risk factors in type 1 diabetes /." Linköping : Department of Clinical and Experimental Medicine, Linköping University, 2008. http://www.bibl.liu.se/liupubl/disp/disp2008/med1075s.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Walker, Kelly N. "Family functioning and diabetic ketoacidosis in pediatric patients with type i diabetes." [Gainesville, Fla.] : University of Florida, 2004. http://purl.fcla.edu/fcla/etd/UFE0004901.

Full text
Abstract:
Thesis (M.S.)--University of Florida, 2004.
Typescript. Title from title page of source document. Document formatted into pages; contains 42 pages. Includes Vita. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
10

Clark, DessyeDee M. "Computer-aided hypoglycemia detection in adolescents with insulin-dependent diabetes mellitus /." Thesis, Connect to this title online; UW restricted, 2001. http://hdl.handle.net/1773/7368.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Type 1 diabetes mellitu"

1

Type 1 diabetes. Oxford: Oxford University Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bluestone, Jeffrey A., Mark Atkinson, and Peter Arvan. Type 1 diabetes. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Barbara, Simon. Type 1 diabetes in adults. Oxford: Oxford University Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Unaue, Emil R., and Hugh O. McDevitt. Immunopathogenesis of type 1 diabetes mellitus. London: Academic, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kaufman, Francine Ratner. Medical management of type 1 diabetes. 6th ed. Alexandria: American Diabetes Association, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gregory, Bock, Goode Jamie, and Novartis Foundation, eds. Defining optimal immunotherapies for type 1 diabetes. Chichester, UK: Wiley-Blackwell, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

W, Bode Bruce, and American Diabetes Association, eds. Medical management of type 1 diabetes. 5th ed. Alexandria, Va: American Diabetes Association, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

S, Eisenbarth George, ed. Immunology of type 1 diabetes. 2nd ed. New York: Kluwer Academic/Plenum Publishers, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

D, Andreani, Kolb Hubert, and Pozzilli Paolo, eds. Immunotherapy of type 1 diabetes. Chichester: Wiley, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Association, American Diabetes, ed. Medical management of type 1 diabetes. 3rd ed. Alexandria, Va: American Diabetes Association, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Type 1 diabetes mellitu"

1

Sonawalla, Ambreen, and Rabab Jafri. "Type 1 Diabetes Mellitus." In Endocrine Conditions in Pediatrics, 307–11. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-52215-5_52.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Woo, Paula, and Kendra B. Baldwin. "Type 1 Diabetes Mellitus." In Adolescent Nutrition, 663–91. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-45103-5_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

O'Reilly, Caryl Ann. "Diabetes Mellitus Type 1." In Clinical Case Studies in Home Health Care, 399–410. West Sussex UK: John Wiley & Sons, Inc., 2013. http://dx.doi.org/10.1002/9781118785744.ch38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Heller, Lois Jane, Celette Sugg Skinner, A. Janet Tomiyama, Elissa S. Epel, Peter A. Hall, Julia Allan, Lara LaCaille, et al. "Type 1 Diabetes Mellitus." In Encyclopedia of Behavioral Medicine, 2012. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_780.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

La Greca, Annette M., and Eleanor R. Mackey. "Type 1 Diabetes Mellitus." In Behavioral Approaches to Chronic Disease in Adolescence, 85–100. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-87687-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

McArdle, Paul. "Type 1 diabetes mellitus." In Dietetic and Nutrition Case Studies, 106–10. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781119163411.ch28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Buschur, Elizabeth O., and Stephanie Lawrence. "Diabetes Mellitus (Type 1)." In Care of Adults with Chronic Childhood Conditions, 131–47. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-43827-6_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Meneghini, Luigi. "Type 1 Diabetes Mellitus." In Encyclopedia of Behavioral Medicine, 2282–83. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_780.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Arampatzis, Adamantios, Lida Mademli, Thomas Reilly, Mike I. Lambert, Laurent Bosquet, Jean-Paul Richalet, Thierry Busso, et al. "Type 1 Diabetes Mellitus." In Encyclopedia of Exercise Medicine in Health and Disease, 883. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-540-29807-6_4566.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bhansali, Anil, and Yashpal Gogate. "Type 1 Diabetes Mellitus." In Clinical Rounds in Endocrinology, 365–91. New Delhi: Springer India, 2015. http://dx.doi.org/10.1007/978-81-322-2398-6_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Type 1 diabetes mellitu"

1

Aprilia, Dinda, Eva Decroli, Alexander Kam, Afdol Rahmadi, Asman Manaf, and Syafril Syahbuddin. "Sepsis in Type 1 Diabetes Mellitus with Diabetic Ketoacidosis." In The 2nd International Conference on Tropical Medicine and Infectious Disease. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009859200720074.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nengroo, Irfan, Kumudu Pematilleke, and Tanya Naydeva. "1316 Type 1 diabetes mellitus: early diagnosis and referral." In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference, Liverpool, 28–30 June 2022. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2022. http://dx.doi.org/10.1136/archdischild-2022-rcpch.458.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ismaili, Doruntina, Fëllënza Spahiu, Lirije Beqiri, and Afërdita Berisha. "Nursing Care in Children with Type 1 Diabetes Mellitus." In University for Business and Technology International Conference. Pristina, Kosovo: University for Business and Technology, 2018. http://dx.doi.org/10.33107/ubt-ic.2018.370.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mohammed, Ahmed, and Alzahraa saber. "Effect of Parvovirus B19 in Diabetes Mellitus Type 1." In Proceedings of 2nd International Multi-Disciplinary Conference Theme: Integrated Sciences and Technologies, IMDC-IST 2021, 7-9 September 2021, Sakarya, Turkey. EAI, 2022. http://dx.doi.org/10.4108/eai.7-9-2021.2314785.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chaofeng Yan, Youqing Wang, and Xifa Sun. "Predictive-retrospective proportional glycemic control for type 1 diabetes mellitus." In 2013 ICME International Conference on Complex Medical Engineering (CME 2013). IEEE, 2013. http://dx.doi.org/10.1109/iccme.2013.6548336.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rodrigues, Fabiana. "Psychotherapy Intervention With Hypnosis In Patients With Type 1 Diabetes Mellitus." In 5th International Congress on Clinical & Counselling Psychology. Cognitive-crcs, 2017. http://dx.doi.org/10.15405/epsbs.2017.05.10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Morales-Contreras, Jonatan, E. Ruiz-Velazquez, and J. A. Garcia-Rodriguez. "Robust glucose control via μ-synthesis in type 1 diabetes mellitus." In 2017 IEEE International Autumn Meeting on Power, Electronics and Computing (ROPEC). IEEE, 2017. http://dx.doi.org/10.1109/ropec.2017.8261671.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Leon, Blanca S., Alma Y. Alanis, Edgar N. Sanchez, Fernando Ornelas-Tellez, and Eduardo Ruiz-Velazquez. "Neural inverse optimal control applied to type 1 diabetes mellitus patients." In 2012 IEEE 3rd Latin American Symposium on Circuits and Systems (LASCAS). IEEE, 2012. http://dx.doi.org/10.1109/lascas.2012.6180310.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lehmann, E. D., T. Deutsch, E. R. Carson, and P. H. Sonksen. "A simulator of glucose-insulin interaction in type 1 diabetes mellitus." In 1992 14th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 1992. http://dx.doi.org/10.1109/iembs.1992.5761298.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lehmann, Deutsch, Carson, and Sonksen. "A Simulator Of Glucose-insulin Interaction In Type 1 Diabetes Mellitus." In Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 1992. http://dx.doi.org/10.1109/iembs.1992.594640.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Type 1 diabetes mellitu"

1

Deo, Salil, David McAllister, Naveed Sattar, and Jill Pell. The time-varying cardiovascular benefits of glucagon like peptide-1 agonist (GLP-RA)therapy in patients with type 2 diabetes mellitus: A meta-analysis of multinational randomized trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2021. http://dx.doi.org/10.37766/inplasy2021.7.0097.

Full text
Abstract:
Review question / Objective: P - patients with type 2 diabetes melllitus already receiving routine medical therapy; I - patients receiving glucagon like peptide 1 receptor agonist (GLP1 receptor agonist) therapy (semaglutide, dulaglutide, liraglutide, exenatide, lixisenatide, efpeglenatide, abiglutide); C - patients receiving standard therapy for diabetes mellitus but not receiving GLP1 agonist therapy; O - composite end point as per invididual trial, cardiovascular mortality, all-cause mortality, myocardial infarction, stoke. Condition being studied: Type 2 diabetes mellitus. Study designs to be included: Randomised controlled trials which enroll a large number of patients (defined as > 500) and are multinational in origin. Studies included will need to have published Kaplan and Meier curves for the end-points presented in the manuscript.
APA, Harvard, Vancouver, ISO, and other styles
2

Luan, Sisi, Wenke Cheng, Chenglong Wang, Hongjian Gong, and Jianbo Zhou. Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0015.

Full text
Abstract:
Review question / Objective: Diabetes is an independent risk factor for cognitive impairment. Little is known regarding the neuroprotective effects of glucagon-like peptide 1 (GLP-1) analogs on type 2 diabetes mellitus (T2DM).Here, the study aim to assess the impact of GLP-1 on general cognition function among patients with T2DM. Eligibility criteria: Inclusion criteria were as follows: (1) an original article was recently published in English, (2) the population included subjects diagnosed with diabetes at baseline, (3) GLP-1 analogs is a single formulation rather than a fixed dose combination, (4) GLP-1 analogs were compared with no GLP-1 use or placebo or self-control before treatment, (5) the duration of antidiabetic agent use was 12 weeks or more, and (6) it provided quantitative measures of general cognitive function assessed by MMSE or MoCA. Exclusion criteria were as follows: (1) the publication was a review, case report, animal study, or letter to the editor, (2) the study did not clearly define clinical outcomes, (3) the authors could not provide valid data after being contacted, (4) duplicated data.
APA, Harvard, Vancouver, ISO, and other styles
3

Silva, Rodrigo Ribeiro e., Mateus de Miranda Gauza, Julia Opolski Nunes da Silva Opolski, and Maria Eduarda Schramm Guisso. Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 for Type 2 Diabetes: A Meta-analysis of Phase 2 Randomized Controlled Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0102.

Full text
Abstract:
Review question / Objective: To compare Once-Weekly Insulin Icodec and Once-Daily Insulin Glargine U100 in patients with Type 2 Diabetes Mellitus using oral hypoglycemic drugs in need of insulin therapy. Condition being studied: Patients with Diabetes Mellitus Type 2 using oral hypoglycemic drugs in need for basal insulin. Eligibility criteria: Inclusion in this meta-analysis was restricted to studies that met all the following criteria: (1) randomized trials; (2) comparing the use once weekly insulin icodec to once daily insulin glargine; (3) enrolling patients with type 1 or type 2 diabetes mellitus; (4) evaluating any of the desired outcomes; (4) articles in written on english language. We excluded studies with (1) no control group; (2) overlapping studies population; clinical trial register entry only; (3) non-human studies and (4) studies reported only as abstracts.
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Wanqing, Fei Huang, and Chunchao Han. Efficacy of Regimens in the Treatment of Latent Autoimmune Diabetes in Adults: A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0072.

Full text
Abstract:
Review question / Objective: Efficacy of Regimens in the Treatment of Latent Autoimmune Diabetes in Adults: A Network Meta-Analysis. Condition being studied: Latent autoimmune diabetes mellitus (LADA) in adults is a highly heterogeneous autoimmune disease with clinical and genetic characteristics between Type 1 Diabetes（T1DM） and Type 2 Diabetes（T2DM）, and therefore there are no uniform criteria for the selection of therapeutic agents. We conducted a web-based meta analysis to evaluate the efficacy of various therapeutic agents for LADA by comparing their effects on various indicators reflecting LADA disease.
APA, Harvard, Vancouver, ISO, and other styles
5

yu, luyou, jinping yang, xi meng, and yanhua ling. Efficacy and safety of acupuncture combined with probiotics in the treatment of type 2 diabetes mellitus with intestinal microbiota disorder: A protocol for systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0001.

Full text
Abstract:
Review question / Objective: Efficacy and safety of acupuncture combined with probiotics in the treatment of type 2 diabetes mellitus with intestinal microbiota disorder: A protocol for systematic review and meta analysis. Eligibility criteria: 1.The literatures of type 2 diabetes patients were included without restriction on gender, age, race, disease course and blood glucose control of the subjects. 2. The relevant literatures included in human intestinal flora do not strictly restrict the test methods and key indicators of fecal specimens. 3. Relevant literatures with no statistically significant difference in general data between the experimental group and the control group were included. 4.There is no restriction on whether blind method or distributive hiding method is used to include Chinese and English literatures whose research type is correlation study. 5. References that clearly indicated standard deviation (SD), mean value or which could be calculated by formula were included.
APA, Harvard, Vancouver, ISO, and other styles
6

Trucco, Massimo. Safe Gene Therapy for Type 1 Diabetes. Fort Belvoir, VA: Defense Technical Information Center, October 2012. http://dx.doi.org/10.21236/ada612662.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Trucco, Massimo. Safe Gene Therapy for Type 1 Diabetes. Fort Belvoir, VA: Defense Technical Information Center, October 2010. http://dx.doi.org/10.21236/ada612978.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Trucco, Massimo. Genetic and Environmental Pathways in Type 1 Diabetes Complications. Fort Belvoir, VA: Defense Technical Information Center, September 2009. http://dx.doi.org/10.21236/ada544029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Trucco, Massimo. Genetic and Environmental Pathways in Type 1 Diabetes Complications. Fort Belvoir, VA: Defense Technical Information Center, September 2010. http://dx.doi.org/10.21236/ada544030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Emily Morton, Emily Morton. T Cell Vaccines as an Immunotherapy for Type 1 Diabetes. Experiment, January 2015. http://dx.doi.org/10.18258/4443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Type 1 diabetes mellitu' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography